Developmental Neuroscience

 

Audiogenic Seizures and Neuronal Deficits following Early Exposure to Barbiturate

Yanai J. · Bergman A. · Shafer R. · Yedwab G. · Tabakoff B.

Author affiliations

Department of Anatomy and Embryology, The Hebrew University-Hadassah Medical School, Jerusalem, Israel; Department of Physiology and Biophysics University of Illinois at the Medical Center, Chicago, Ill., USA; Department of Obstetrics and Gynecology, Hakirya Maternity Hospital, Sakler University, Tel Aviv, Israel

Related Articles for ""

Dev Neurosci 1981;4:345–350

Log in to MyKarger to check if you already have access to this content.


Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 9.00 *
EUR 8.00 *
USD 9.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: December 18, 2007
Issue release date: 1981

Number of Print Pages: 6
Number of Figures: 0
Number of Tables: 0

ISSN: 0378-5866 (Print)
eISSN: 1421-9859 (Online)

For additional information: https://www.karger.com/DNE

Abstract

Sabramice (n = 232) received phenobarbital (PhB) during the period of their prenatal development (PB group), or during the period of their neonatal development (NB group). PB mice received the barbiturate transplacentally by feeding their mothers PhB in their diet (3 g/kg food) on gestation days 9–18. NB mice received daily injections of PhB on postnatal days 2–21. On postnatal days 28–31 subjects were tested for their susceptibility to audiogenic seizures. Only 10% of the PB mice seized, a rate similar to the 13% of controls. However, the seizure rate of NB mice was three times higher than controls (37%, p < 0.001). Sample groups were kept until day 50 and their brains removed and saved for quantitative histological analysis of the hippocampal neurons. In PB mice, there was only a small deficit in the number of the hippocampal pyramidal neurons compared to controls (15%, p < 0.01), and no deficit in the granule cells. On the other hand, NB mice sustained a 35% deficit in the number of the pyramidal cells (p < 0.001) and a 21% deficit in the granule cells (p < 0.01). The sensitive period for the neuronal damage corresponded with the sensitive period for changes in seizures. Although other parts of the brain are also involved in seizure, the correlation of the seizure with the hippocampus is important because the hippocampus is one of the major structures determining seizure.

© 1981 S. Karger AG, Basel




Related Articles:


Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: December 18, 2007
Issue release date: 1981

Number of Print Pages: 6
Number of Figures: 0
Number of Tables: 0

ISSN: 0378-5866 (Print)
eISSN: 1421-9859 (Online)

For additional information: https://www.karger.com/DNE


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
TOP